International guidelines on access to biologic therapy: why the differences and which is best?

[1]  M. Dougados,et al.  Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. , 2007, Joint, bone, spine : revue du rhumatisme.

[2]  P. Emery,et al.  Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go? , 2007, Arthritis research & therapy.

[3]  B. Bresnihan,et al.  QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries , 2007, Annals of the rheumatic diseases.

[4]  D. Scott,et al.  Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). , 2006, Rheumatology.

[5]  R. Luqmani,et al.  Updating the BSR Guidelines for Anti-TNF therapy in Adult RA (again) , 2006 .

[6]  F. Wolfe,et al.  The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. , 2005, Arthritis and rheumatism.

[7]  M. Østergaard,et al.  Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent , 2005, Annals of the rheumatic diseases.

[8]  A. Brennan,et al.  The NICE reappraisal of biologics in 2005: what rheumatologists need to know. , 2005, Rheumatology.